Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.970
+0.035 (1.81%)
Aug 14, 2025, 9:01 AM - Market open
Spero Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 48.58 | 47.98 | 103.78 | 53.51 | 18.26 | 9.33 | Upgrade
|
| Revenue Growth (YoY) | -58.99% | -53.77% | 93.95% | 193.10% | 95.67% | -48.59% | Upgrade
|
| Cost of Revenue | 79.98 | 96.76 | 51.44 | 47.59 | 64.53 | 67 | Upgrade
|
| Gross Profit | -31.4 | -48.78 | 52.34 | 5.92 | -46.27 | -57.67 | Upgrade
|
| Selling, General & Admin | 24.96 | 23.7 | 25.55 | 36.48 | 41.7 | 21.44 | Upgrade
|
| Operating Expenses | 24.96 | 23.7 | 25.55 | 36.48 | 41.7 | 21.44 | Upgrade
|
| Operating Income | -56.36 | -72.48 | 26.79 | -30.57 | -87.97 | -79.11 | Upgrade
|
| Interest Expense | - | - | - | -2.61 | -1.94 | - | Upgrade
|
| Interest & Investment Income | 4.74 | 4.74 | 3.94 | 1.11 | 0.35 | 0.4 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | - | 0.43 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.84 | 0.06 | -0.01 | 0.86 | -0.19 | - | Upgrade
|
| EBT Excluding Unusual Items | -52.47 | -67.69 | 30.71 | -31.2 | -89.76 | -78.28 | Upgrade
|
| Merger & Restructuring Charges | -1.14 | -0.88 | - | -11.63 | - | - | Upgrade
|
| Asset Writedown | - | - | -5.31 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -3.58 | - | - | Upgrade
|
| Pretax Income | -53.6 | -68.57 | 25.4 | -46.42 | -89.76 | -78.28 | Upgrade
|
| Income Tax Expense | - | - | 2.6 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -53.6 | -68.57 | 22.81 | -46.42 | -89.76 | -78.28 | Upgrade
|
| Net Income | -53.6 | -68.57 | 22.81 | -46.42 | -89.76 | -78.28 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.55 | Upgrade
|
| Net Income to Common | -53.6 | -68.57 | 22.81 | -46.42 | -89.76 | -78.83 | Upgrade
|
| Shares Outstanding (Basic) | 55 | 54 | 53 | 38 | 31 | 22 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 54 | 53 | 38 | 31 | 22 | Upgrade
|
| Shares Change (YoY) | 2.68% | 1.98% | 40.98% | 21.65% | 38.01% | 23.27% | Upgrade
|
| EPS (Basic) | -0.97 | -1.27 | 0.43 | -1.23 | -2.91 | -3.52 | Upgrade
|
| EPS (Diluted) | -0.98 | -1.27 | 0.43 | -1.23 | -2.91 | -3.52 | Upgrade
|
| Free Cash Flow | - | -23.44 | -33 | -7.73 | -64.35 | -86.03 | Upgrade
|
| Free Cash Flow Per Share | - | -0.43 | -0.62 | -0.21 | -2.08 | -3.84 | Upgrade
|
| Gross Margin | -64.64% | -101.67% | 50.43% | 11.06% | -253.45% | - | Upgrade
|
| Operating Margin | -116.02% | -151.08% | 25.81% | -57.13% | -481.87% | -847.94% | Upgrade
|
| Profit Margin | -110.34% | -142.91% | 21.98% | -86.74% | -491.65% | -844.90% | Upgrade
|
| Free Cash Flow Margin | - | -48.86% | -31.79% | -14.45% | -352.47% | -922.07% | Upgrade
|
| EBITDA | -56.36 | -72.48 | 27.15 | -29.7 | -87.33 | -78.35 | Upgrade
|
| EBITDA Margin | -116.02% | -151.08% | 26.16% | -55.50% | - | - | Upgrade
|
| D&A For EBITDA | 0 | 0 | 0.37 | 0.87 | 0.65 | 0.76 | Upgrade
|
| EBIT | -56.36 | -72.48 | 26.79 | -30.57 | -87.97 | -79.11 | Upgrade
|
| EBIT Margin | -116.02% | -151.08% | 25.81% | -57.13% | - | - | Upgrade
|
| Effective Tax Rate | - | - | 10.23% | - | - | - | Upgrade
|
| Revenue as Reported | 48.58 | 47.98 | 103.78 | 53.51 | 18.26 | 9.33 | Upgrade
|
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.